Research
Hormonal
Obesity-induced CNS insulin and leptin resistance is driven by impaired blood-brain barrier transport, chronic low-grade inflammation (TNF-alpha, IL-6), and upregulation of negative regulators like SOCS3 and PTP1B.
In obesity, the brain stops listening to leptin and insulin due to inflammation and transport issues. This resistance is a key barrier to weight loss. Addressing inflammation and improving metabolic health may help restore the brain's ability to regulate weight.
GoodSupportsHIGH confidence
The first obstruction that both leptin and insulin must surpass is the blood–brain barrier (BBB)... A more direct impact on leptin signaling has been linked to the low-level chronic inflammation found in obesity... SOCS3 is also an inhibitor of insulin signaling... PTP1B... may dephosphorylate JAKs, STATs, the IR as well as IRS proteins.
Why this rating
Based on multiple studies linking inflammation, BBB transport, and specific protein regulators to resistance.
Source
CNS leptin and insulin action in the control of energy homeostasis
Bengt‐Frederik Belgardt et al. · Annals of the New York Academy of Sciences · 2010
DOI 10.1111/j.1749-6632.2010.05799.x
narrative_reviewCited 272×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Central nervous system (CNS) action of leptin and insulin is essential for maintaining body weight and fuel metabolism, with hypothalamic neurons (specifically POMC and AGRP/NPY populations) serving as primary mediators of their anorexigenic effects.Good
- CNS insulin signaling regulates systemic glucose homeostasis primarily through POMC neurons, whereas its effect on body weight involves additional, less-defined neuronal populations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →